A real-world multicenter retrospective prospective clinical study of the efficacy and safety of Ensartinib capsules in patients with advanced ALK-positive non-small cell lung cancer

Status

Active, not recruiting

Phases

Phase 4

Study type

Observational

Source

ChiCTR

Registry ID

ChiCTR2200057754

Enrollment

Unknown

Registered

2022-03-16

Start date

2022-03-18

Completion date

Unknown

Last updated

2023-11-13

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

non-small cell lung cancer (NSCLC)

Interventions

Experimental group:Ensartinib

Eligibility

Sex/Gender

All

Age

18 Years to No maximum

Inclusion criteria

Inclusion criteria: 1. Aged >=18 years (minors involved in the protection of vulnerable groups); 2. Patients with locally advanced or advanced ALK (+) NSCLC who are intended to receive ensartinib therapy (intended to receive: at investigator's discretion); 3. Signed knowledge (independent knowledge with ethical consent); 4. There is no restriction on combination therapy.

Exclusion criteria

Exclusion criteria: Ensatinib was treated, but no objective efficacy was evaluated.

Design outcomes

Primary

Measure	Time frame
Objective Response Rate;	—

Secondary

Measure	Time frame
Disease Control Rate;Progression-Free Survival;Duration of Response;Intracranial Objective Response Rate;Overall Survival;Adverse Events;	—

Countries

China

Contacts

Public ContactLi Xiaoyan

Beijing Tiantan Hospital, Capital Medical University

sharerha@126.com+86 13466383808

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026